ArticleFrontiers in oncology2025
Long term survival following cryoablation with adjuvant Toripalimab for anorectal malignant melanoma: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cryoablation as an organ-preserving therapy for low rectal cancer a comprehensive protocol and institutional perspective.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anorectal malignant melanoma is a rare subtype of melanoma with a poor prognosis. Despite this, some patients decline Miles' operation due to the sigmoid colostomies that follow abdominoperineal resections in cases of anorectal malignant melanoma. Case report: We report the case of an 80-year-old woman diagnosed with anorectal malignant melanoma who underwent cryosurgery accompanied by adjuvant PD-1 therapy to maintain anal sphincter function. The results indicated that we successfully achieved the goal of sphincter preservation and therapeutic efficacy. The patient derived significant benefits from the cryoablation treatment. Conclusions: Ultrasound-guided trans-anal cryoablation, when combined with adjuvant PD-1 therapy, offers a novel treatment approach for patients with anorectal malignant melanoma. Our results have confirmed the advantages of this treatment regimen, particularly for those desiring to retain anal sphincter function. Further studies are required to substantiate the efficacy of ultrasound-guided trans-anal cryoablation with adjuvant Toripalimab and to elucidate its underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.